Narcolepsy Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Treatment, Product, and Region

Description

List of Tables

The narcolepsy therapeutics market size is expected to reach USD 7,852.93 million by 2034, according to a new study by Polaris Market Research. The report "Narcolepsy Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Treatment (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The narcolepsy therapeutics market involves the development and commercialization of treatments aimed at managing the symptoms of narcolepsy. Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and, in some cases, cataplexy. The rising awareness of narcolepsy, increasing diagnosis rates, and an expanding patient population drive the narcolepsy therapeutics market growth.

Key drivers include advancements in drug development, such as the introduction of novel treatments with fewer side effects and once-daily formulations. Opportunities exist in underpenetrated regions such as Asia Pacific and Latin America, where healthcare access is improving. Narcolepsy therapeutics market trends such as the integration of digital health solutions, combination therapies, and a growing focus on pediatric treatments are further shaping the market. The overall growth is fueled by the ongoing need for effective narcolepsy treatments to improve the quality of life for patients.

Narcolepsy Therapeutics Market Report Highlights

Based on treatment, the narcolepsy with cataplexy segment dominated the narcolepsy therapeutics market share in 2024 due to the high prevalence of cataplexy among narcolepsy patients and the availability of effective treatments such as sodium oxybate. However, the narcolepsy without cataplexy segment is growing steadily as treatments for excessive daytime sleepiness gain traction.
In terms of product, the sodium oxybate segment dominated the narcolepsy therapeutics market revenue in 2024, owing to its proven efficacy in treating both cataplexy and excessive daytime sleepiness in narcolepsy patients. The central nervous system stimulants segment is showing strong growth as a primary treatment for managing sleepiness.
North America held the major market share in 2024 due to advanced healthcare infrastructure and high awareness levels. However, Asia Pacific is the fastest-growing region, fueled by improving healthcare access and rising awareness of narcolepsy.

Polaris Market Research has segmented the narcolepsy therapeutics market report on the basis of treatment, product, and region:

By Treatment Outlook (Revenue - USD Million, 2020-2034)

Narcolepsy with Cataplexy
Narcolepsy without Cataplexy
Secondary Narcolepsy

By Product Outlook (Revenue - USD Million, 2020-2034)

Central Nervous System Stimulants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Tricyclic Antidepressants
Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1304

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Narcolepsy Therapeutics Market Insights

4.1. Narcolepsy Therapeutics Market - Market Snapshot
4.2. Narcolepsy Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.2. Restraints and Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Narcolepsy Therapeutics Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Narcolepsy Therapeutics Market, by Treatment

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
5.3. Narcolepsy With Cataplexy
- 5.3.1. Global Narcolepsy Therapeutics Market, by Narcolepsy With Cataplexy, by Region, 2020-2034 (USD Million)
5.4. Narcolepsy Without Cataplexy
- 5.4.1. Global Narcolepsy Therapeutics Market, by Narcolepsy Without Cataplexy, by Region, 2020-2034 (USD Million)
5.5. Secondary Narcolepsy
- 5.5.1. Global Narcolepsy Therapeutics Market, by Secondary Narcolepsy, by Region, 2020-2034 (USD Million)

6. Global Narcolepsy Therapeutics Market, by Product

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
6.3. Central Nervous System Stimulants
- 6.3.1. Global Narcolepsy Therapeutics Market, by Central Nervous System Stimulants, by Region, 2020-2034 (USD Million)
6.4. Sodium Oxybate
- 6.4.1. Global Narcolepsy Therapeutics Market, by Sodium Oxybate, by Region, 2020-2034 (USD Million)
6.5. Selective Serotonin Reuptake Inhibitor
- 6.5.1. Global Narcolepsy Therapeutics Market, by Selective Serotonin Reuptake Inhibitor, by Region, 2020-2034 (USD Million)
6.6. Tricyclic Antidepressants
- 6.6.1. Global Narcolepsy Therapeutics Market, by Tricyclic Antidepressants, by Region, 2020-2034 (USD Million)
6.7. Others
- 6.7.1. Global Narcolepsy Therapeutics Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Narcolepsy Therapeutics Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Narcolepsy Therapeutics Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Narcolepsy Therapeutics Market - North America
- 7.3.1. North America: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
- 7.3.2. North America: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.3.3. Narcolepsy Therapeutics Market - U.S.
  - 7.3.3.1. U.S.: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.3.4. Narcolepsy Therapeutics Market - Canada
  - 7.3.4.1. Canada: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
7.4. Narcolepsy Therapeutics Market - Europe
- 7.4.1. Europe: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
- 7.4.2. Europe: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.3. Narcolepsy Therapeutics Market - UK
  - 7.4.3.1. UK: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.4. Narcolepsy Therapeutics Market - France
  - 7.4.4.1. France: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.4.2. France: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.5. Narcolepsy Therapeutics Market - Germany
  - 7.4.5.1. Germany: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.6. Narcolepsy Therapeutics Market - Italy
  - 7.4.6.1. Italy: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.7. Narcolepsy Therapeutics Market - Spain
  - 7.4.7.1. Spain: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.8. Narcolepsy Therapeutics Market - Netherlands
  - 7.4.8.1. Netherlands: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.9. Narcolepsy Therapeutics Market - Russia
  - 7.4.9.1. Russia: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.10. Narcolepsy Therapeutics Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
7.5. Narcolepsy Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.3. Narcolepsy Therapeutics Market - China
  - 7.5.3.1. China: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.3.2. China: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.4. Narcolepsy Therapeutics Market - India
  - 7.5.4.1. India: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.4.2. India: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.5. Narcolepsy Therapeutics Market - Malaysia
  - 7.5.5.1. Malaysia: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.6. Narcolepsy Therapeutics Market - Japan
  - 7.5.6.1. Japan: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.7. Narcolepsy Therapeutics Market - Indonesia
  - 7.5.7.1. Indonesia: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.8. Narcolepsy Therapeutics Market - South Korea
  - 7.5.8.1. South Korea: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.9. Narcolepsy Therapeutics Market - Australia
  - 7.5.9.1. Australia: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.10. Narcolepsy Therapeutics Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
7.6. Narcolepsy Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.3. Narcolepsy Therapeutics Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.4. Narcolepsy Therapeutics Market - UAE
  - 7.6.4.1. UAE: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.5. Narcolepsy Therapeutics Market - Israel
  - 7.6.5.1. Israel: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.6. Narcolepsy Therapeutics Market - South Africa
  - 7.6.6.1. South Africa: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.7. Narcolepsy Therapeutics Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
7.7. Narcolepsy Therapeutics Market - Latin America
- 7.7.1. Latin America: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
- 7.7.2. Latin America: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.3. Narcolepsy Therapeutics Market - Mexico
  - 7.7.3.1. Mexico: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.4. Narcolepsy Therapeutics Market - Brazil
  - 7.7.4.1. Brazil: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.5. Narcolepsy Therapeutics Market - Argentina
  - 7.7.5.1. Argentina: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.6. Narcolepsy Therapeutics Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Jazz Pharmaceuticals plc
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Teva Pharmaceutical Industries Ltd.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Takeda Pharmaceutical Company Limited
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Avadel Pharmaceuticals plc
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Harmony Biosciences Holdings, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Axsome Therapeutics, Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Arena Pharmaceuticals, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. BIOPROJET
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Graymark Healthcare, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Addrenex Pharmaceuticals, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development